Search

Purpose: The CoVID-TE model was developed with the aim of predicting venous thrombotic events (VTE) in cancer patients with Sars-Cov-2 infection. Moreover, it was capable of predicting hemorrhage and mortality 30 days following infection diagnosis. The model is pending validation., Methods/patients: Multicenter retrospective study (10 centers). Adult patients with active oncologic disease/ antineoplastic therapy with Sars-Cov-2 infection hospitalized between March 1, 2020 and March 1. 2022 were recruited. The primary endpoint was to study the association between the risk categories of the CoVID-TE model and the occurrence of thrombosis using the Chi-Square test. Secondary endpoints were to demonstrate the association between these categories and the occurrence of post-diagnostic Sars-Cov-2 bleeding/ death events. The Kaplan-Meier method was also used to compare mortality by stratification., Results: 263 patients were enrolled. 59.3% were men with a median age of 67 years. 73.8% had stage IV disease and lung cancer was the most prevalent tumor (24%). A total of 86.7% had an ECOG 0-2 and 77.9% were receiving active antineoplastic therapy. After a median follow-up of 6.83 months, the incidence of VTE, bleeding, and death 90 days after Sars-Cov-2 diagnosis in the low-risk group was 3.9% (95% CI 1.9-7.9), 4.5% (95% CI 2.3-8.6), and 52.5% (95% CI 45.2-59.7), respectively. For the high-risk group it was 6% (95% CI 2.6-13.2), 9.6% (95% CI 5.0-17.9), and 58.0% (95% CI 45.3-66.1). The Chi-square test for trends detected no statistically significant association between these variables (p > 0.05). Median survival in the low-risk group was 10.15 months (95% CI 3.84-16.46), while in the high-risk group it was 3.68 months (95% CI 0.0-7.79). The differences detected were not statistically significant (p = 0.375)., Conclusions: The data from our series does not validate of the CoVID-TE as a model to predict thrombosis, hemorrhage, or mortality in cancer patients with Sars-Cov-2 infection., (© 2023. The Author(s).)

Introduction: Introduction: malnutrition is a common problem in cancer patients that worsens during hospitalization and is associated with increased morbidity and mortality, and impaired quality of life. Objectives: to describe the effect of implementing a nutritional assessment and support protocol on the nutritional status of hospitalized cancer patients. Methods: a prospective, cross-sectional, non-controlled, quasi-experimental study in cancer patients admitted to an oncology service consecutively regardless of their nutritional status between September 2019 and March 2020. Anthropometric parameters, body composition, and hand grip strength were measured at admission and discharge. The percentage of patients with malnutrition, dynapenia, and sarcopenia at admission and discharge was calculated. Results: a total of 90 cancer patients participated in this study (mean age: 66 years, 67.8 % men); 33.2 % of the patients had a tumor in the gastrointestinal tract and 73.3 % of the patients were in stage IV; 95 % required nutritional support (nutritional supplementation, enteral nutrition or parenteral nutrition). After the nutritional intervention, no differences were found in the anthropometric parameters with a mean weight loss of 0.1, although improvements in body composition were observed. The percentage of malnourished patients remained stable on admission and discharge regardless of the criteria used. Conclusions: the implementation of a protocol for assessment and nutritional support at admission in cancer patients may help prevent or delay the worsening of their nutritional status during hospital stay.